Rosanna Ricafort is Vice President, Head of Cell Therapy Clinical Development at Bristol
Myers Squibb. In this role, she is a member of the Cell Therapy Leadership Team and
drives the implementation of globally aligned, regional regulatory strategies to bring
late-stage CAR T assets to market. Dr. Ricafort has been with BMS since 2015 and has held increasing leadership positions in Immuno-Oncology Research and Development.
She was responsible for multiple development programs across solid tumors and hematologic malignancies and led the clinical due diligence of Bristol Myers Squibb’s acquisition of Celgene, one of the largest acquisitions in the healthcare industry to date.
Prior to joining BMS, Dr. Ricafort started her industry career at Celgene, where she
supported the multiple myeloma franchise leading clinical studies and delivering
o Dr. Ricafort is a pediatric hematologist/oncologist and bone marrow transplant
physician by training; she established and directed the Pediatric Blood and Marrow
Transplantation Program at Montefiore Medical Center, NY, where she held a faculty
appointment for over 10 years. She earned her Medical Doctorate at Mount Sinai School
of Medicine and completed her fellowship training in Pediatric Hematology and
Oncology at Memorial Sloan-Kettering Cancer Center in New York. She was a research
fellow in MSKCC-Sloan Kettering Institute's Department of Human Genetics and
Immunology working on gene transfer and adoptive cellular therapy strategies in the lab
of Michel Sadelain - whose pioneering work revolutionized the treatment of cancer.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.